• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非黑色素瘤皮肤癌死亡率。一项基于人群的研究。

Nonmelanoma skin cancer mortality. A population-based study.

作者信息

Weinstock M A, Bogaars H A, Ashley M, Litle V, Bilodeau E, Kimmel S

机构信息

Department of Medicine, Veterans Affairs Medical Center, Providence, RI 02908.

出版信息

Arch Dermatol. 1991 Aug;127(8):1194-7.

PMID:1863078
Abstract

To estimate the magnitude of nonmelanoma skin cancer mortality and describe its parameters, we reviewed the medical records of all deaths certified as due to this cause among Rhode Island residents from 1979 through 1987. After excluding acquired immunodeficiency syndrome-associated Kaposi's sarcoma, we confirmed that nonmelanoma skin cancer was the cause of death for 51 individuals, a quarter of the number of melanoma deaths reported. The age-adjusted nonmelanoma skin cancer mortality rate was 0.44/10(5) per year. Fifty-nine percent were due to squamous cell carcinoma, and 20% were due to basal cell carcinoma. Most appeared actinically induced. Among deaths from squamous cell carcinoma, the mean age was 73 years. At least 80% of the squamous cell carcinomas metastasized, and 47% arose on the ear. None appeared due to refusal of treatment. Among deaths from basal cell carcinoma, the mean age was 85 years, and refusal of surgical intervention was documented in 40%. Study of nonmelanoma skin cancer mortality provides for estimation of the magnitude of this problem, complements other studies of prognosis, and helps guide prevention, early detection, and treatment.

摘要

为了估算非黑素瘤皮肤癌的死亡率并描述其参数,我们查阅了1979年至1987年罗德岛居民中所有被证明死于该病因的死亡病历。在排除与获得性免疫缺陷综合征相关的卡波西肉瘤后,我们确认非黑素瘤皮肤癌是51人的死因,这一数字是报告的黑素瘤死亡人数的四分之一。年龄调整后的非黑素瘤皮肤癌死亡率为每年0.44/10万。59%的死亡归因于鳞状细胞癌,20%归因于基底细胞癌。大多数似乎是光化性诱导的。在鳞状细胞癌死亡病例中,平均年龄为73岁。至少80%的鳞状细胞癌发生了转移,47%发生在耳部。没有一例是因拒绝治疗而死亡。在基底细胞癌死亡病例中,平均年龄为85岁,40%有拒绝手术干预的记录。对非黑素瘤皮肤癌死亡率的研究有助于估算这一问题的严重程度,补充其他预后研究,并有助于指导预防、早期发现和治疗。

相似文献

1
Nonmelanoma skin cancer mortality. A population-based study.非黑色素瘤皮肤癌死亡率。一项基于人群的研究。
Arch Dermatol. 1991 Aug;127(8):1194-7.
2
Nonmelanoma skin cancer mortality (1988-2000): the Rhode Island follow-back study.非黑色素瘤皮肤癌死亡率(1988 - 2000年):罗德岛随访研究
Arch Dermatol. 2004 Jul;140(7):837-42. doi: 10.1001/archderm.140.7.837.
3
Craniofacial resection for nonmelanoma skin cancer of the head and neck.头颈部非黑色素瘤皮肤癌的颅面切除术。
Laryngoscope. 2005 Jun;115(6):931-7. doi: 10.1097/01.MLG.0000163766.66223.97.
4
Malignant eyelid tumours in Taiwan.台湾的恶性眼睑肿瘤。
Eye (Lond). 2003 Mar;17(2):216-20. doi: 10.1038/sj.eye.6700231.
5
Skin cancer mortality in Germany before and after the post-communist transition.德国后共产主义转型前后的皮肤癌死亡率。
Int J Dermatol. 2009 Apr;48(4):363-70. doi: 10.1111/j.1365-4632.2009.03892.x.
6
[Non-melanoma skin cancer as a cause of death in Denmark].[非黑色素瘤皮肤癌作为丹麦的一种死因]
Ugeskr Laeger. 1991 Feb 18;153(8):582-4.
7
Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island Follow-Back Study.
J Invest Dermatol. 1994 Jun;102(6):6S-9S. doi: 10.1111/1523-1747.ep12385735.
8
Deaths from non-melanoma skin cancer in Western Australia.西澳大利亚州非黑色素瘤皮肤癌导致的死亡病例
Cancer Causes Control. 2008 Oct;19(8):879-85. doi: 10.1007/s10552-008-9150-9. Epub 2008 Apr 2.
9
Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach.德国北莱茵 - 威斯特法伦州的恶性黑色素瘤和非黑色素瘤皮肤癌:基于患者与基于诊断的发病率研究方法
Int J Dermatol. 2007 Jun;46(6):564-70. doi: 10.1111/j.1365-4632.2006.03056.x.
10
Non-melanoma skin cancer and ten-year all-cause mortality: a population-based cohort study.非黑色素瘤皮肤癌与十年全因死亡率:一项基于人群的队列研究。
Acta Derm Venereol. 2010 Jul;90(4):362-7. doi: 10.2340/00015555-0899.

引用本文的文献

1
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.PD-1 抑制在治疗局部晚期或转移性基底细胞癌中的临床活性。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004839.
2
Photoprotection for Skin of Color.肤色皮肤的光保护。
Am J Clin Dermatol. 2022 Mar;23(2):195-205. doi: 10.1007/s40257-021-00670-z. Epub 2022 Jan 19.
3
Citrus Consumption and the Risk of Non-Melanoma Skin Cancer in the Women's Health Initiative.妇女健康倡议中的柑橘类水果消费与非黑色素瘤皮肤癌风险
Cancers (Basel). 2021 Apr 30;13(9):2173. doi: 10.3390/cancers13092173.
4
Global gene expression of histologically normal primary skin cells from BCNS subjects reveals "single-hit" effects that are influenced by rapamycin.基底细胞痣综合征(BCNS)患者组织学正常的原代皮肤细胞的全基因组表达揭示了受雷帕霉素影响的“单次打击”效应。
Oncotarget. 2019 Feb 15;10(14):1360-1387. doi: 10.18632/oncotarget.26640.
5
All-cause mortality in patients with basal and squamous cell carcinoma: A systematic review and meta-analysis.基底细胞癌和鳞状细胞癌患者的全因死亡率:系统评价和荟萃分析。
J Am Acad Dermatol. 2018 Apr;78(4):663-672.e3. doi: 10.1016/j.jaad.2017.11.026. Epub 2017 Nov 13.
6
Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.制定基底细胞癌临床试验的核心结局指标集:一项文献系统综述及运用德尔菲法确定核心结局指标集的研究方案
Trials. 2017 Oct 23;18(1):490. doi: 10.1186/s13063-017-2244-5.
7
Epidemiological trends in skin cancer.皮肤癌的流行病学趋势
Dermatol Pract Concept. 2017 Apr 30;7(2):1-6. doi: 10.5826/dpc.0702a01. eCollection 2017 Apr.
8
Detection and Discrimination of Non-Melanoma Skin Cancer by Multimodal Imaging.多模态成像在非黑素瘤皮肤癌的检测与鉴别诊断中的应用。
Healthcare (Basel). 2013 Oct 17;1(1):64-83. doi: 10.3390/healthcare1010064.
9
Sex hormones and the risk of keratinocyte cancers among women in the United States: A population-based case-control study.美国女性性激素与角质形成细胞癌风险:一项基于人群的病例对照研究。
Int J Cancer. 2016 Jul 15;139(2):300-9. doi: 10.1002/ijc.30072. Epub 2016 Apr 15.
10
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.晚期基底细胞癌、刺猬信号通路及治疗选择——平滑化抑制剂的作用
Biologics. 2015 Nov 6;9:129-40. doi: 10.2147/BTT.S54179. eCollection 2015.